We meet you at your stage, from formation through exit, with anything from a focused sprint to an ongoing partnership.
Each engagement is shaped around the decision in front of you, and we stay tightly involved from the first call to the final recommendation.
Where do we win first? What will customers pay, and through which channel?
We size the real market and shape the pricing, channel, positioning, and launch that turn a product into traction. That includes the recurring-revenue strategy across instruments, consumables, and service that decides whether a tools business is durable, and a go-to-market built for both global and emerging markets.
Does the technology do what it claims? Is the market as ready as the deck says?
We run commercial and technical diligence for venture and growth investors, model the market and the valuation, identify targets worth pursuing, and stay on after the deal to help the portfolio company deliver.
Should we build, buy, or partner? How do we integrate without losing what we bought?
We work the build, buy, or partner decision, screen and diligence targets, plan the integration so the value survives the deal, and prepare a company and its story for an exit.
Where does AI create durable advantage in our business, and where is it only hype?
We help platform companies position their AI and data across Genomics, Spatial Biology, and Oncology, design the business and partnership models that turn them into revenue, and guide incumbents deciding how to answer AI-native entrants.
We need a senior operator now, a board member who has actually run this, or a coach for the person who has to.
We step in as a fractional or interim CEO, chief commercial officer, or general manager, serve on boards and scientific advisory boards, coach founders and first-time CEOs, and build commercial teams from an operator's seat.
Across this industry we go deep in five areas, each one a place where the experience is hands-on, current, and earned in the operator's seat.
Having developed a Spatial Biology business through its highest-growth years, we know where the science is real, where the commercial models work, and how to build a category that customers and partners take seriously.
From sequencing to clinical Genomics, we have launched the platforms, integrated the acquisitions, and built the commercial engines, so we understand both the technology and the economics that decide who wins.
Foundation models, multimodal data, and machine learning are rewriting how discovery and Diagnostics get done. We help platform companies sharpen the technical story, build the data moats and model-driven products that compound over time, and convert AI capability into real partnerships, defensible advantage, and revenue.
A category long underbuilt and now drawing serious capital. We help founders and investors size the real opportunity, navigate the clinical and reimbursement realities, and build commercial strategies suited to how this market adopts.
We have taken Point of Care Diagnostics through development, regulatory clearance, reimbursement, and retail, including work with the FDA and CMS, so we know what it takes to move a test from the bench to the patient.